Coronary/Structural Heart

FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Sept. 12, 2018 FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy /PRNewswire/ — Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Praluent® (alirocumab) Injection, a PCSK9 inhibitor. The […]

MEDTRONIC STATEMENT REGARDING RECENT FDA WARNING LETTERS

DUBLIN – September 11, 2018 – Today, Medtronic issued the following statement confirming it has received FDA warning letters (CMS #560736 and #562437) related to its Cardiac Rhythm and Heart Failure facilities located in Mounds View, Minn., and in Juncos, Puerto Rico. The warning letters reflect earlier FDA inspection reports from […]

RenalGuard Solutions Debuts Newly Formed Reprieve Cardiovascular at Heart Failure Society of America Annual Meeting and Completes $7 Million Financing

MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular™, a newly formed company affiliated with RenalGuard Solutions™, is a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF). RenalGuard also announced the completion of a $7 million financing provided by strong support from existing investors and Abiomed, […]

CellAegis Announces Completion of Patient Enrollment in First North American Study for Innovative Heart Attack Therapy Using autoRIC®

TORONTO, Sept. 11, 2018 (GLOBE NEWSWIRE) — CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced completion of patient enrollment in a large scale, investigator sponsored study (“FIRST”) to evaluate the clinical […]

Baylis Medical Expands Transseptal Portfolio with Launch of Steerable Guiding Sheath

TORONTO, Sept. 10, 2018 /PRNewswire/ – Baylis Medical Company, a leader in the development, manufacturing and commercialization of cardiology devices, announced the official commercial launch of its SureFlex® Steerable Guiding Sheath. The SureFlex sheath is part of Baylis’ rapidly growing portfolio of high-performance products for transseptal access. The sheath features an advanced sheath-to-dilator […]

Seqster joins American Heart Association Center for Health Technology and Innovation

SAN DIEGO, Sept. 11, 2018 /PRNewswire/ — Seqster the leading consumer-centric health data management platform empowering employees, members, or patients to collect, own and share all of their health data, today joined the American Heart Association’s Center for Health Technology and Innovation (CHTI) Health Tech Collaborative. The collaboration will combine AHA’s data-driven approaches with Seqster’s […]

Paragonix Technologies, Inc., Announces Clinical Use of the Paragonix SherpaPak™ Cardiac Transport System in World-Renowned Transplant Centers

BRAINTREE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc., a Boston-based commercial-stage medical device company, announced today, a successful series of clinical use, of the Paragonix SherpaPak™ Cardiac Transport System (CTS) at a leading Boston-based hospital and other world-renowned transplant centers in the United States and in Europe. The Paragonix SherpaPak™ CTS1,2 is intended for […]

LivaNova Welcomes NICE Interventional Procedures Guidance on Sutureless Aortic Valve Replacement

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, welcomes the recently updated interventional procedures guidance for sutureless aortic valve replacement issued by the U.K. National Institute for Health and Care Excellence (NICE), which states that sutureless aortic valve replacement is an alternative to conventional surgical aortic valve replacement. The […]

Ancora Heart Announces Key Activities for Transcatheter Cardiovascular Therapeutics 2018

SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the company’s key activities at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation in San Diego. Interim data will be presented from the recently expanded […]

ImpediMed SOZO® Abstract Presentations at Key Scientific Cardiology Meetings Demonstrate Utilization of Bioimpedance Spectroscopy for Heart Failure Patients

BRISBANE, Australia & CARLSBAD, Calif.–(BUSINESS WIRE)–ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces that two abstracts demonstrating utilization of its SOZO® device will be presented during poster presentations by A.J. Accardi, M.D. at the upcoming American […]